Characterization of olanzapine-induced weight gain in rats

  title={Characterization of olanzapine-induced weight gain in rats},
  author={Andrew J. Goudie and Judith A. Smith and Jason Cg Halford},
  journal={Journal of Psychopharmacology},
  pages={291 - 296}
Novel antipsychotic drugs (APDs) have enhanced therapeutic actions compared to ‘typical’ APDs. However,clinical studies indicate that some induce marked weight gain. We attempted to model this effect in female Wistar rats given olanzapine chronically at 4 mg/kg b.i.d (4.5 h between injections). Such rats showed marked weight gain, which was statistically significant after only a single day of treatment, although weight gain increased up to a plateau after 10 days of treatment. Cessation of… 

Figures from this paper

A parametric analysis of olanzapine-induced weight gain in female rats
It is suggested that olanzapine-induced hyperphagia acts as an initial stimulus which leads to weight gain, enhanced visceral adiposity and subsequent insulin resistance, although the latter may be ameliorated by compensatory responses in adiponectin levels.
Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model
It is demonstrated that olanzapine-induced body weight gain can partially be reduced by co-treatment with betahistine, which has H3 receptor antagonistic effects to increase histamine release, which may augment its direct agonistic effects on H1 receptors.
Modelling olanzapine-induced weight gain in rats.
The effects of olanzapine on energy balance observed in different rat models are summarized and some of the factors that appear to contribute to the inconsistencies in observed effects are discussed.
Inhibition of olanzapine-induced weight gain by the retinoid analog AM-80.
It is suggested that AM-80 is a potential therapeutic agent to attenuate weight gain and metabolic side effects associated with olanzapine.
Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain
Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats
Assessment of body weight in the present model may not have predictive validity, and other measures may be needed to differentiate between WG-inducing and weight-neutral drugs.


Association of olanzapine-induced weight gain with an increase in body fat.
The weight gain during antipsychotic treatment with olanzapine was mainly attributable to an increase in body fat; patients' lean body mass did not change.
Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone
Weight gain induced by clozapine
Mechanism of the neuroleptic-induced obesity in female rats
Bodyweight Gain with Atypical Antipsychotic
Although many questions concerning the pathogenesis of bodyweight gain remain unresolved, this adverse effect has to be taken into consideration when prescribing the atypical antipsychotics, particularly in view its affect on compliance during long term treatment and the long term effects of obesity on mortality and morbidity.
Studies on modulation of feeding behavior by atypical antipsychotics in female mice
  • G. Kaur, S. Kulkarni
  • Psychology, Medicine
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2002
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
BACKGROUND Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R
Effect of amantadine on weight gain during olanzapine treatment
Novel antipsychotics: comparison of weight gain liabilities.
The relative receptor affinities of the novel antipsychotics for histamine H1 appear to be the most robust correlate of these clinical findings.
The clinical implications of weight gain in schizophrenia.
Clinical relevance of increased body weight in schizophrenia is focused on and screening and management options to prevent and/or manage weight gain associated with schizophrenia in everyday clinical practice are outlined.